The agreement will facilitate Tissue Regenix’s entry into the $1bn global tissue heart valve market.
The agreement gives Tissue Regenix exclusive worldwide rights (excluding Brazil) to the clinical data which will support commercialization of ‘dCELL Heart Valve.’
Tissue Regenix has obtained exclusive worldwide commercialization rights (excluding Brazil) to all future decellularised products as part of an agreed development plan which includes a decellularised version of a commercially available bioprosthetic heart valve, which has over 5 years of clinical data and has been implanted in over 1200 patients.
The company will also accelerate the development of new applications for its exciting product pipeline, which includes alternate applications for its patch product and the porcine dCELL Heart Valve, in conjunction with PUCPR utilizing their world class facilities in Brazil.
Initially Tissue Regenix will work with their UK development partner to transfer the technology for use in the NHS and also commercialise it in the rest of the world (excluding Brazil) via a licensing programme to other tissue banks.
Tissue Regenix MD Antony Odell said the global heart valve market represents a major opportunity for the company and they look forward to commercializing the dCELL Heart Valve and making this product available worldwide to surgeons and patients.
